P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION. (23rd June 2022) - Jaeger, U.; Broome, C.; Go, R.; Patriarca, A.; Roeth, A.; Chang, Q.; Weedin, N.; Adams, P.; Cahir-McFarland, E.; Kroon, H.-A.